Table 1.
Mechanism of Action | Effects on Hepatic Steatosis | Animal Evidence | Human Evidence | Extrahepatic Benefits | Safety |
---|---|---|---|---|---|
AMPK | ↓ steatosis | Aerobic and resistance training increases AMPK activation | N.A. | ↑ GLUT-4 expression | Exercise is safe for people with NAFLD/NASH when supervised by an appropriately qualified exercise professional and with adequate screening and monitoring protocols. |
↑ glucose uptake | |||||
FGF-19 and -21 | ↓ steatosis | Aerobic exercise training increases FGF receptor 1 and FGF receptor 2 Chronic exercise training increases β-klotho Chronic exercise training reduces serum FGF-21 |
Aerobic and resistance training reduces serum FGF-21 | ↑ hepatic glycogen synthesis | |
Effect of exercise on FGF-19 is unclear | ↑ hepatic gluconeogenesis | ||||
GLP-1 | ↓ steatosis | N.A. | Acute aerobic exercise ↑ GLP-1 | ↑ weight loss | |
Short term high-intensity aerobic exercise reversed GLP-1 resistance | ↑ insulin production | ||||
N.A. for chronic training adaptation | ↓ appetite | ||||
Mitochondrial function and β-oxidation | ↓ steatosis | Exercise training improves mitochondrial function, ↑ mitochondrial content and ↑ β-oxidation | Exercise training improves mitochondrial function, ↑ mitochondrial content and ↑ β-oxidation | ↑ insulin sensitivity | |
UCP | ↓ steatosis | Aerobic exercise upregulates UCP-1 and reverses UCP-2 dysfunction in the liver | N.A. | Prevent oxidative stress | |
PPAR-α/γ | ↓ steatosis | Exercise training (moderate-intensity running or swimming; high-intensity interval training; resistance training) activates PPAR-α | N.A. | ↑ insulin sensitivity | |
Maternal aerobic exercise may protect against early life NAFLD in offspring | |||||
THR-β | ↓ steatosis | Aerobic exercise training increases T3 response index | N.A. | Acute exercise ↑ free T3 and T4 | |
↑ mitochondria size and number | |||||
↑ glucose uptake | |||||
↑ gluconeogenesis | |||||
Chronic exercise ↑ T3 and T4 turnover at same absolute intensity |
AMPK = adenosine monophosphate-activated protein kinase; FGF = fibroblast growth factor; GLP = glucagon-like peptide; GLUT = glucose transporter type; N.A. = not available; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis; PPAR = peroxisome proliferator-activated receptor; T3 = triiodothyronine; T4 = thyroxine; THR = thyroid hormone receptor; UCP = mitochondrial uncoupling proteins.